Fig. 2.
Overall survival (OS) curves of EGFR-mutated patients treated with TKIs. a OS curves of patients with EGFR 19 del and L858R mutation who received first-line TKI therapy (34.9 vs. 37.5 months, P = 0.566); b OS curves of patients with the EGFR 19 del and L858R mutation who received second-line or greater TKI therapy (26.7 vs. 23.8 months, P = 0.256)